The biopharmaceutics of successful controlled release drug product: Segmental-dependent permeability of glipizide vs. metoprolol throughout the intestinal tract

International Journal of Pharmaceutics

Volumn 489, Issue 1-2, 2015, Pages 304-310

  Zur, Moran ^a   Cohen, Noa ^a   Agbaria, Riad ^a   Dahan, Arik ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

BCS classification; Controlled release dosage form; Intestinal permeability; Regioselective absorption; Segmental dependent permeability

Indexed keywords

GLIPIZIDE; METOPROLOL; ANTIDIABETIC AGENT; ARTIFICIAL MEMBRANE; DELAYED RELEASE FORMULATION;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG PENETRATION; DRUG SOLUBILITY; ILEUM; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; INTESTINE PERFUSION; NONHUMAN; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; ADMINISTRATION AND DOSAGE; ANIMAL; ARTIFICIAL MEMBRANE; CACO 2 CELL LINE; CHEMISTRY; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; HUMAN; INTESTINE ABSORPTION; MALE; METABOLISM; PERMEABILITY; PHARMACEUTICS; PHARMACOKINETICS; SOLUBILITY; WISTAR RAT;

ANIMALS; BIOPHARMACEUTICS; CACO-2 CELLS; DELAYED-ACTION PREPARATIONS; GLIPIZIDE; HUMANS; HYPOGLYCEMIC AGENTS; INTESTINAL ABSORPTION; INTESTINES; MALE; MEMBRANES, ARTIFICIAL; METOPROLOL; PERMEABILITY; RATS, WISTAR; SOLUBILITY;

EID: 84929192402     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.05.002     Document Type: Article

References (64)

1. G.L. Amidon, H. Lennernäs, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 1995 413 420
2. A. Beig, J.M. Miller, and A. Dahan Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption Eur. J. Pharm. Biopharm. 81 2012 386 391
3. A. Beig, R. Agbaria, and A. Dahan Oral delivery of lipophilic drugs: the tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations PLoS One 8 2013 e68237
4. A. Beig, J.M. Miller, and A. Dahan The interaction of nifedipine with selected cyclodextrins and the subsequent solubility-permeability trade-off Eur. J. Pharm. Biopharm. 85 2013 1293 1299
5. M. Berelowitz, C. Fischette, W. Cefalu, D.S. Schade, T. Sutfin, and I.A. Kourides Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM Diabetes Care 17 1994 1460 1464
6. G. Carruthers, R. Shearer, W. Taylor, and M. Moore A comparison of a controlled release (CR/ZOK) formulation of metoprolol, once daily, with conventional metoprolol tablets, twice daily, in mild to moderate hypertension J. Clin. Pharmacol. 30 1990 S61 S65
7. CDER/FDA Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Dosage Forms Based on a Biopharmaceutical Slassification System 2000 Center for Drug Evaluation and Research
8. M. Chung, I. Kourides, W. Canovatchel, T. Sutfin, M. Messig, and R.L. Chaiken Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate-release glipizide in patients with type II diabetes mellitus J. Clin. Pharmacol. 42 2002 651 657
9. O. Corrigan The biopharmaceutic drug classification and drugs administered in extended release (ER) formulations D. Young, J. Devane, J. Butler, In Vitro-In Vivo Correlations 1997 Springer US 111 128
10. A. Dahan, and G. Amidon Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of P-gp Pharm. Res. 26 2009 883 892
11. A. Dahan, and G.L. Amidon Segmental dependent transport of low permeability compounds along the small intestine due to P-gp: the role of efflux transport in the oral absorption of BCS class III drugs Mol. Pharm. 6 2009 19 28
12. A. Dahan, and G.L. Amidon Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting Am. J. Physiol.-Gastrointest. Liver Physiol. 297 2009 G371 G377
13. A. Dahan, and G.L. Amidon MRP2 mediated drug-drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting Int. J. Pharm. 386 2010 216 220
14. A. Dahan, R. Duvdevani, E. Dvir, A. Elmann, and A. Hoffman A novel mechanism for oral controlled release of drugs by continuous degradation of a phospholipid prodrug along the intestine: in-vivo and in-vitro evaluation of an indomethacin-lecithin conjugate J. Control. Release 119 2007 86 93
15. A. Dahan, and A. Hoffman Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs J. Control. Release 129 2008 1 10
16. A. Dahan, and J. Miller The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs AAPS J. 14 2012 244 251
17. A. Dahan, J. Miller, and G. Amidon Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs AAPS J. 11 2009 740 746
18. A. Dahan, H. Sabit, and G. Amidon The H2 receptor antagonist nizatidine is a P-gp substrate: characterization of its intestinal epithelial cell efflux transport AAPS J. 11 2009 205 213
19. A. Dahan, B.T. West, and G.L. Amidon Segmental-dependent membrane permeability along the intestine following oral drug administration: evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat Eur. J. Pharm. Sci. 36 2009 320 329
20. A. Dahan, J.M. Miller, J.M. Hilfinger, S. Yamashita, L.X. Yu, H. Lennernäs, and G.L. Amidon High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations Mol. Pharm. 7 2010 1827 1834
21. A. Dahan, J.M. Miller, A. Hoffman, G.E. Amidon, and G.L. Amidon The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone J. Pharm. Sci. 99 2010 2739 2749
22. A. Dahan, A. Beig, V. Ioffe-Dahan, R. Agbaria, and J. Miller The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: increased apparent solubility and drug flux through the intestinal membrane AAPS J. 15 2013 347 353
23. A. Dahan, O. Wolk, Y.H. Kim, C. Ramachandran, G.M. Crippen, T. Takagi, M. Bermejo, and G.L. Amidon Purely in silico BCS classification: science based quality standards for the world's drugs Mol. Pharm. 10 2013 4378 4390
24. S.S. Davis, J.G. Hardy, and J.W. Fara Transit of pharmaceutical dosage forms through the small intestine Gut 27 1986 886 892
25. S. Dhawan, B. Singh, S. Kumar Garg, D. Hota, R. Dash, A. Singla, and V. Sinha Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers Clin. Pharmacokinet. 45 2006 317 324
26. M. Fairstein, R. Swissa, and A. Dahan Regional-dependent intestinal permeability and BCS classification: elucidation of pH-related complexity in rats using pseudoephedrine AAPS J. 15 2013 589 597
27. R.H. Foster, and G.L. Plosker Glipizide: a review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus PharmacoEconomics 18 2000 289 306
28. L.K. Gram, G.M. Rist, H. Lennernäs, and B. Steffansen Impact of carriers in oral absorption: permeation across Caco-2 cells for the organic anions estrone-3-sulfate and glipizide Eur. J. Pharm. Sci. 37 2009 378 386
29. Y. Henchoz, D. Guillarme, S. Martel, S. Rudaz, J.-L. Veuthey, and P.-A. Carrupt Fast log P determination by ultra-high-pressure liquid chromatography coupled with UV and mass spectrometry detections Anal. Bioanal. Chem. 394 2009 1919 1930
30. G. Jobin, A. Cortot, J. Godbillon, M. Duval, J. Schoeller, J. Hirtz, and J. Bernier Investigation of drug absorption from the gastrointestinal tract of man. I. Metoprolol in the stomach, duodenum and jejunum Br. J. Clin. Pharmacol. 19 1985 97S 105S
31. B.W. Karlson, M. Dellborg, L. Gullestad, J. Åberg, J. Sugg, and J. Herlitz A pharmacokinetic and pharmacodynamic comparison of immediate-release metoprolol and extended-release metoprolol CR/XL in patients with suspected acute myocardial infarction: a randomized, open-label study Cardiology 127 2014 73 82
32. N.A. Kasim, M. Whitehouse, C. Ramachandran, M. Bermejo, H. Lennernäs, A.S. Hussain, H.E. Junginger, S.A. Stavchansky, K.K. Midha, V.P. Shah, and G.L. Amidon Molecular properties of WHO essential drugs and provisional biopharmaceutical classification Mol. Pharm. 1 2004 85 96
33. R. Kulkarni, N. Yumibe, Z. Wang, X. Zhang, C.C. Tang, K. Ruterbories, A. Cox, R. McCain, and G.T. Knipp Comparative pharmacokinetics studies of immediate- and modified-release formulations of glipizide in pigs and dogs J. Pharm. Sci. 101 2012 4327 4336
34. E. Leaf, and J. King Patient outcomes after formulary conversion from immediate-release to extended-release glipizide tablets Am. J. Health-Syst. Pharm. 56 1999 454 456
35. H. Lennernäs Human jejunal effective permeability and its correlation with preclinical drug absorption models J. Pharm. Pharmacol. 49 1997 627 638
36. H. Lennernäs Human intestinal permeability J. Pharm. Sci. 87 1998 403 410
37. H. Lennernäs Animal data: the contributions of the Ussing chamber and perfusion systems to predicting human oral drug delivery in vivo Adv. Drug Deliv. Rev. 59 2007 1103 1120
38. H. Lennernäs Intestinal permeability and its relevance for absorption and elimination Xenobiotica 37 2007 1015 1051
39. H. Lennernäs Human in vivo regional intestinal permeability: importance for pharmaceutical drug development Mol. Pharm. 11 2014 12 23
40. H. Lennernäs Regional intestinal drug permeation: biopharmaceutics and drug development Eur. J. Pharm. Sci. 57 2014 333 341
41. I. Lozoya-Agullo, M. Zur, O. Wolk, A. Beig, I. González-Álvarez, M. González-Álvarez, M. Merino-Sanjuán, M. Bermejo, and A. Dahan In-situ intestinal rat perfusions for human Fabs prediction and BCS permeability class determination: investigation of the single-pass vs. the Doluisio experimental approaches Int. J. Pharm. 480 2015 1 7
42. D.T. Manallack The acid-base profile of a contemporary set of drugs: implications for drug discovery SAR QSAR Environ. Res. 20 2009 611 655
43. Y. Masaoka, Y. Tanaka, M. Kataoka, S. Sakuma, and S. Yamashita Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract Eur. J. Pharm. Sci. 29 2006 240 250
44. J.M. Miller, A. Beig, R.A. Carr, J.K. Spence, and A. Dahan A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability Mol. Pharm. 9 2012 2009 2016
45. J.M. Miller, A. Beig, R.A. Carr, G.K. Webster, and A. Dahan The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations Mol. Pharm. 9 2012 581 590
46. J.M. Miller, A. Beig, B.J. Krieg, R.A. Carr, T.B. Borchardt, G.E. Amidon, G.L. Amidon, and A. Dahan The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation Mol. Pharm. 8 2011 1848 1856
47. J.M. Miller, A. Dahan, D. Gupta, S. Varghese, and G.L. Amidon Quasi-equilibrium analysis of the ion-pair mediated membrane transport of low-permeability drugs J. Control. Release 137 2009 31 37
48. J.M. Miller, A. Dahan, D. Gupta, S. Varghese, and G.L. Amidon Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir Mol. Pharm. 7 2010 1223 1234
49. J.A.G. Morais, and M.d.R. Lobato The new European Medicines Agency guideline on the investigation of bioequivalence Basic Clin. Pharmacol. Toxicol. 106 2010 221 225
50. D.M. Mudie, G.L. Amidon, and G.E. Amidon Physiological parameters for oral delivery and in vitro testing Mol. Pharm. 7 2010 1388 1405
51. P. Omvik, J. Leer, H. Istad, and G. Westergren Equal efficacy and improved tolerability with 50 mg controlled-release metoprolol compared with 100 mg conventional metoprolol in hypertensive patients Am. J. Ther. 1 1994 65 73
52. C.G. Regardh, K.O. Borg, R. Johansson, G. Johnsson, and L. Palmer Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man J. Pharmacokinet. Biopharm. 2 1974 347 364
53. D.C. Simonson, I.A. Kourides, M. Feinglos, H. Shamoon, C.T. Fischette, and Group T.G., G.T.S.S. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group Diabetes Care 20 1997 597 606
54. S. Sutton, L. Evans, J. Fortner, J. McCarthy, and K. Sweeney Dog colonoscopy model for predicting human colon absorption Pharm. Res. 23 2006 1554 1563
55. T. Takagi, C. Ramachandran, M. Bermejo, S. Yamashita, L.X. Yu, and G.L. Amidon A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan Mol. Pharm. 3 2006 631 643
56. C. Tannergren, A. Bergendal, H. Lennernäs, and B. Abrahamsson Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment Mol. Pharm. 6 2009 60 73
57. A.L. Ungell, S. Nylander, S. Bergstrand, Å. Sjöberg, and H. Lennernäs Membrane transport of drugs in different regions of the intestinal tract of the rat J. Pharm. Sci. 87 1998 360 366
58. J.G. Wagner, and A.J. Sedman Quantitaton of rate of gastrointestinal and buccal absorption of acidic and basic drugs based on extraction theory J. Pharmacokinet. Pharmacodyn. 1 1973 23 50
59. D. Winne Shift of pH-absorption curves J. Pharmacokinet. Biopharm. 5 1977 53 94
60. O. Wolk, R. Agbaria, and A. Dahan Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development Drug Des. Dev. Ther. 8 2014 1563 1575
61. Y. Yang, P.J. Faustino, D.A. Volpe, C.D. Ellison, R.C. Lyon, and L.X. Yu Biopharmaceutics classification of selected β-blockers: solubility and permeability class membership Mol. Pharm. 4 2007 608 614
62. L.X. Yu, E. Lipka, J.R. Crison, and G.L. Amidon Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption Adv. Drug Deliv. Rev. 19 1996 359 376
63. M. Zur, M. Gasparini, O. Wolk, G.L. Amidon, and A. Dahan The low/high BCS permeability class boundary: physicochemical comparison of metoprolol and labetalol Mol. Pharm. 11 2014 1707 1714
64. M. Zur, A.S. Hanson, and A. Dahan The complexity of intestinal permeability: assigning the correct BCS classification through careful data interpretation Eur. J. Pharm. Sci. 61 2014 11 17